The shortage of semaglutide injections (Ozempic, Wegovy) is over, the FDA announced on Friday. The agency, along with maker Novo Nordisk, confirmed that supply now meets or exceeds both the current ...

Shares of wellness-product platform Hims & Hers Health Inc. tumbled on Friday after the Food and Drug Administration said the ...

The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S.

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

The FDA declared the end of the shortage of Novo Nordisk’s Wegovy and Ozempic, impacting compounding pharmacies selling ...

Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s expected to curtail widespread access to cheaper copies of the popular ...

According to the FDA, there is no longer a shortage of semaglutide, the active ingredient in the wildly popular Ozempic and Wegovy — a very bad omen for the countless telehealth and pharmacy ...

In December, the FDA declared that shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., ...